Rigel Pharma: Key RA Drug Data Expected Late 2012 Through H1 2013 Seeking Alpha R548 (oral JAK3 inhibitor) is currently in Phase 1 clinical development to treat organ transplant rejection. RIGL enjoys a strong balance sheet with $202.6M in cash and equivalents along with no debt as of 6/30/12, although the Company has an ... |
